Metformin may alter the course of Leber’s hereditary optic neuropathy: a case report

Leber's hereditary optic neuropathy (LHON) is a rare inherited mitochondrial disease caused by variants in mitochondrial DNA (mtDNA) transmitted exclusively through the maternal line. The disease predominantly affects young males and is characterized by progressive bilateral vision loss. Idebenone, a well-studied drug, modestly enhances the mitochondrial function and visual acuity in many patients with LHON. In this study, we report the case of a 48-year-old woman diagnosed with LHON (m.11778G>A/<i>MT-ND4</i>) and type 2 diabetes mellitus who experienced visual field improvement following metformin treatment after 26 months of progressive vision loss unresponsive to idebenone, nicotinamide adenine dinucleotide (NAD+), and hormone replacement therapy (HRT). Our findings offer an intriguing perspective on LHON management but require more investigations, particularly on the molecular effects of metformin on the mitochondrial function in LHON patients.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2025-08-19
DOI
https://doi.org/10.3389/fmed.2025.1609941
Primary Topic
Metabolism, Diabetes, and Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metformin may alter the course of Leber’s hereditary optic neuropathy: a case report

Danny Gauthier, Maryam Golmohammadi, Valério Carelli, Alfredo A. Sadun et al.
Frontiers in Medicine
Metabolism, Diabetes, and Cancer
article

Metformin may alter the course of Leber’s hereditary optic neuropathy: a case report

Danny Gauthier, Maryam Golmohammadi, Valério Carelli, Alfredo A. Sadun, Nutsa Pargalava, Shenoda Abd Elmaseh
article en

Abstract

Leber's hereditary optic neuropathy (LHON) is a rare inherited mitochondrial disease caused by variants in mitochondrial DNA (mtDNA) transmitted exclusively through the maternal line. The disease predominantly affects young males and is characterized by progressive bilateral vision loss. Idebenone, a well-studied drug, modestly enhances the mitochondrial function and visual acuity in many patients with LHON. In this study, we report the case of a 48-year-old woman diagnosed with LHON (m.11778G>A/<i>MT-ND4</i>) and type 2 diabetes mellitus who experienced visual field improvement following metformin treatment after 26 months of progressive vision loss unresponsive to idebenone, nicotinamide adenine dinucleotide (NAD+), and hormone replacement therapy (HRT). Our findings offer an intriguing perspective on LHON management but require more investigations, particularly on the molecular effects of metformin on the mitochondrial function in LHON patients.

Frontiers in MedicineVol. 12
University of California, Los Angeles (US), Doheny Eye Institute (US), Institute of Neurological Sciences (IT), Istituto delle Scienze Neurologiche di Bologna (IT), University of Bologna (IT)
Openalex Percentile: Top 81%
Metabolism, Diabetes, and Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.